What this means
This is a trial sign-up, and it has not reported results yet. It plans to take blood samples from patients before and during treatment with pembrolizumab.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
- Trial ID
- NCT06733987 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Hodgkin Lymphoma
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Ages
- 18 Years to no maximum
- Dates
- First posted Dec 13, 2024 · updated Dec 13, 2024
Registry summary
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken:
- before starting treatment with pembrolizumab.
- undergoing therapy with pembrolizumab (cycle 2 (C2), C3, C4, C8, C12).
Sites (1)
- IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Italy